.png)
Inspira Technologies
Respiratory/extracorporeal life support (ART100 CPB/ECMO; ART500 awake oxygenation) + HYLA non-invasive blood sensor
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
Inspira Technologies is positioned as a commercial-stage respiratory medtech company using FDA-cleared legacy infrastructure to pursue next-generation awake-respiration and blood-monitoring platforms. Its strategy appears to combine regulated-product commercialization with pipeline expansion and selective portfolio monetization into adjacent dual-use markets.[7][10][12]
Efficiency Ratio
The company shows meaningful technical and regulatory output for a relatively small organization, but the limited team size and modest operating footprint suggest output is still being generated with constrained resources rather than scaled operational leverage.[3][6][11]
Evidence Signals
Commercial-stage positioning around the FDA-cleared INSPIRA ART100 system, approved for cardiopulmonary bypass in the U.S. and ECMO procedures outside the U.S.
Development of INSPIRA ART500, described as a next-generation oxygenation system designed for awake, spontaneously breathing patients.
Advancement of HYLA, a proprietary real-time blood sensor platform for continuous, non-invasive monitoring.
Public-company disclosure and investor-relations activity indicate Nasdaq listing and active capital-markets communication.
Company profile sources indicate a small operating base, with employee counts reported around 37 to 48 people in late 2024.
The company reports a headquarters in Ra'anana, Israel, with a single primary office location visible in public profiles.
SEC materials describe a pipeline including ART Gen 2, Cardi-ART, and HYLA blood sensor, indicating continued R&D breadth.
- About
- Israeli commercial-stage medical-device company (Inspira Technologies Ltd.; Nasdaq: IINN; HQ Ra'anana, Israel; founded 2018; ~11-50 staff) specializing in advanced respiratory/life support and real-time blood monitoring. Its FDA-cleared INSPIRA ART100 system is approved for cardiopulmonary bypass in the US and used for ECMO (extracorporeal membrane oxygenation) outside the US; it serves as the foundation for the next-generation INSPIRA ART500 (in development), designed to deliver oxygenation while patients remain awake and spontaneously breathing — an alternative to conventional mechanical ventilation. Inspira is also developing HYLA, a proprietary non-invasive blood-sensor platform for continuous monitoring. Defense relevance: acute respiratory / extracorporeal life support is relevant to severe-casualty resuscitation and critical-care transport (dual-use), with no defense-specific contract confirmed.
- Tags
- #respiratory #ecmo #cardiopulmonarybypass #lifesupport #criticalcare #ventilation #art100 #fda #nasdaq #dualuse